Skip to main content
Top
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Cervical Cancer | Research

Secular trends in incidence and mortality of cervical cancer in India and its states, 1990-2019: data from the Global Burden of Disease 2019 Study

Authors: Mayank Singh, Ravi Prakash Jha, Neha Shri, Krittika Bhattacharyya, Priyanka Patel, Deepak Dhamnetiya

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

Cervical cancer is the fourth most common cancer that occurs to women worldwide. This study aims to assess trends in incidence and mortality of cervical cancer in India and its states over past three decades for tracking the progress of strategies for the prevention and control of cervical cancer.

Methods

Data on cervical cancer incidence and mortality from 1990 to 2019 for India and its states were extracted from Global Burden of Disease study and were utilized for the analysis. Spatial and rank map has been used to see the changes in incidence and mortality of cervical cancer in different Indian states. Further, joinpoint regression analysis is applied to determine the magnitude of the time trends in the age standardized incidence and mortality rates of cervical cancer. We obtained the average annual percent change (AAPC) and corresponding 95% confidence intervals (CI) for each state.

Results

Overall, from 1990 to 2019 Jharkhand (Incidence: -50.22%; Mortality: -56.16%) recorded the highest percentage decrement in cervical cancer incidence and mortality followed by the Himachal Pradesh (Incidence: -48.34%; Mortality: -53.37%). Tamilnadu (1st rank), Jammu & Kashmir and Ladakh (32nd rank) maintained the same rank over the period of three decade for age standardized cervical cancer incidence and mortality. The regression model showed a significant declining trend in India between 1990 and 2019 for age standardized incidence rate (AAPC: −0.82; 95%CI: −1.39 to −0.25; p < 0.05) with highest decline in the period 1998-2005 (AAPC: −3.22; 95%CI: −3.83 to −2.59; p < 0.05). Similarly, a significant declining trend was observed in the age standardized mortality rate of India between 1990 and 2019(AAPC: −1.35; 95%CI: −1.96 to −0.75; p < 0.05) with highest decline in the period 1998-2005 (AAPC: −3.52; 95%CI: −4.17 to −2.86; p < 0.05).

Conclusion

Though the incidence and mortality of cervical cancer declined over past three decades but it is still a major public health problem in India. Information, education and communication activities for girls, boys, parents and community for the prevention and control of cervical cancer should be provided throughout the country.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.CrossRef Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13(8):790–801.CrossRef
4.
go back to reference Das BC, Sharma JK, Gopalkrishna V, Das DK, Singh V, Gissmann L, et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol. 1992a;36(4):239–45.CrossRef Das BC, Sharma JK, Gopalkrishna V, Das DK, Singh V, Gissmann L, et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol. 1992a;36(4):239–45.CrossRef
5.
go back to reference Moghissi KS, Mack HC. Epidemiology of cervical cancer: study of a prison population. Am J Obstet Gynecol. 1968;100(5):607–14.CrossRef Moghissi KS, Mack HC. Epidemiology of cervical cancer: study of a prison population. Am J Obstet Gynecol. 1968;100(5):607–14.CrossRef
6.
go back to reference Farooqui HH, Zodpey S. Cervical cancer control in India: taking evidence to action. J Public Health Policy. 2012;33(2):165–72.CrossRef Farooqui HH, Zodpey S. Cervical cancer control in India: taking evidence to action. J Public Health Policy. 2012;33(2):165–72.CrossRef
7.
go back to reference Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334(21):1362–6.CrossRef Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med. 1996;334(21):1362–6.CrossRef
8.
go back to reference Park MJ, Park EC, Choi KS, Jun JK, Lee HY. Sociodemographic gradients in breast and cervical cancer screening in Korea: the Korean National Cancer Screening Survey (KNCSS) 2005-2009. BMC Cancer. 2011;11(1):1–8.CrossRef Park MJ, Park EC, Choi KS, Jun JK, Lee HY. Sociodemographic gradients in breast and cervical cancer screening in Korea: the Korean National Cancer Screening Survey (KNCSS) 2005-2009. BMC Cancer. 2011;11(1):1–8.CrossRef
9.
go back to reference Krishnan S, Madson E, Porterfield D, Varghese B. Advancing cervical cancer prevention in India: insights from research and programs; 2013. Krishnan S, Madson E, Porterfield D, Varghese B. Advancing cervical cancer prevention in India: insights from research and programs; 2013.
10.
go back to reference Srinivasan S, Johari V, Jesani A. Cervical cancer screening in India. Ethics dumping. Berlin: Springer; 2018. p. 33e48. Srinivasan S, Johari V, Jesani A. Cervical cancer screening in India. Ethics dumping. Berlin: Springer; 2018. p. 33e48.
13.
go back to reference GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.CrossRef GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.CrossRef
14.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applicationsto cancer rates. Stat Med. 2000;19:335–51.CrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applicationsto cancer rates. Stat Med. 2000;19:335–51.CrossRef
15.
go back to reference Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change intrend analysis. Stat Med. 2009;28:3670–82.CrossRef Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change intrend analysis. Stat Med. 2009;28:3670–82.CrossRef
16.
go back to reference Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomized trial. Lancet. 2007;370(9585):398–406.CrossRef Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomized trial. Lancet. 2007;370(9585):398–406.CrossRef
17.
go back to reference Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer cervix in India. Indian J Med Res. 2009;130(3):219–21.PubMed Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer cervix in India. Indian J Med Res. 2009;130(3):219–21.PubMed
18.
go back to reference Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:F12–23.CrossRef Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:F12–23.CrossRef
19.
go back to reference Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016;37(4):278.CrossRef Bobdey S, Sathwara J, Jain A, Balasubramaniam G. Burden of cervical cancer and role of screening in India. Indian J Med Paediatr Oncol. 2016;37(4):278.CrossRef
21.
go back to reference Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, et al. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol. 2018;19(10):1289–306.CrossRef Dhillon PK, Mathur P, Nandakumar A, Fitzmaurice C, Kumar GA, Mehrotra R, et al. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. Lancet Oncol. 2018;19(10):1289–306.CrossRef
22.
go back to reference Badwe RA, Dikshit R, Laversanne M, Bray F. Cancer incidence trends in India. Jpn J Clin Oncol. 2014;44(5):401–7.CrossRef Badwe RA, Dikshit R, Laversanne M, Bray F. Cancer incidence trends in India. Jpn J Clin Oncol. 2014;44(5):401–7.CrossRef
23.
go back to reference Knaul FM, Adami HO, Adebamowo C, Arreola-Ornelas H, Berger AJ, Bhadelia A, et al. The global cancer divide: an equity imperative. In: Closing the cancer divide: an equity imperative. Cambridge: Harvard Global Equity Initiative; 2012. p. 29–60. Knaul FM, Adami HO, Adebamowo C, Arreola-Ornelas H, Berger AJ, Bhadelia A, et al. The global cancer divide: an equity imperative. In: Closing the cancer divide: an equity imperative. Cambridge: Harvard Global Equity Initiative; 2012. p. 29–60.
24.
go back to reference Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262–73.CrossRef Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262–73.CrossRef
25.
go back to reference Sriplung H, Singkham P, Iamsirithaworn S, Jiraphongsa C, Bilheem S. Success of a cervical cancer screening program: trends in incidence in songkhla, southern Thailand, 1989-2010, and prediction of future incidences to 2030. Asian Pac J Cancer Prev. 2014;15(22):10003–8.CrossRef Sriplung H, Singkham P, Iamsirithaworn S, Jiraphongsa C, Bilheem S. Success of a cervical cancer screening program: trends in incidence in songkhla, southern Thailand, 1989-2010, and prediction of future incidences to 2030. Asian Pac J Cancer Prev. 2014;15(22):10003–8.CrossRef
26.
go back to reference Murthy NS, Chaudhry K, Saxena S. Trends in cervical cancer incidence–Indian scenario. Eur J Cancer Prev. 2005;14(6):513–8.CrossRef Murthy NS, Chaudhry K, Saxena S. Trends in cervical cancer incidence–Indian scenario. Eur J Cancer Prev. 2005;14(6):513–8.CrossRef
27.
go back to reference Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.CrossRef Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22(12):2675–86.CrossRef
28.
go back to reference Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(suppl 8):S4–S66.CrossRef Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001;37(suppl 8):S4–S66.CrossRef
29.
go back to reference Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Prevent Biomark. 2010;19(8):1893–907.CrossRef Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Prevent Biomark. 2010;19(8):1893–907.CrossRef
30.
go back to reference Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.CrossRef Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203.CrossRef
31.
go back to reference Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, et al. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020;15(9):e0238291.CrossRef Chauhan AS, Prinja S, Srinivasan R, Rai B, Malliga JS, Jyani G, et al. Cost effectiveness of strategies for cervical cancer prevention in India. PLoS One. 2020;15(9):e0238291.CrossRef
32.
go back to reference Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003;9(5):348–59.CrossRef Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J. 2003;9(5):348–59.CrossRef
33.
go back to reference Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976–2005: an age–period–cohort analysis. Br J Cancer. 2011;105(5):723–30.CrossRef Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F. Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976–2005: an age–period–cohort analysis. Br J Cancer. 2011;105(5):723–30.CrossRef
34.
go back to reference Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2021;73(2):203-11. Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2021;73(2):203-11.
36.
go back to reference International Institute for Population Sciences (IIPS) and ICF. National Family Health Survey (NFHS-4), 2015-16: India. Mumbai: IIPS; 2017. International Institute for Population Sciences (IIPS) and ICF. National Family Health Survey (NFHS-4), 2015-16: India. Mumbai: IIPS; 2017.
37.
go back to reference Das BC, Gopalkrishna V, Sharma JK, Roy M, Luthra UK. Human papillomavirus DNA in urine of women with preneoplastic and neoplastic cervical lesions. Lancet. 1992b;340(8832):1417–8.CrossRef Das BC, Gopalkrishna V, Sharma JK, Roy M, Luthra UK. Human papillomavirus DNA in urine of women with preneoplastic and neoplastic cervical lesions. Lancet. 1992b;340(8832):1417–8.CrossRef
38.
go back to reference Sureshkumar BT, Shanmughapriya S, Das BC, Natarajaseenivasan K. A population-based study of the prevalence of HPV in three districts of Tamil Nadu, India. Int J Gynecol Obstet. 2015;129(1):58–61.CrossRef Sureshkumar BT, Shanmughapriya S, Das BC, Natarajaseenivasan K. A population-based study of the prevalence of HPV in three districts of Tamil Nadu, India. Int J Gynecol Obstet. 2015;129(1):58–61.CrossRef
39.
go back to reference Patel KR, Vajaria BN, Begum R, Desai A, Patel JB, Shah FD, et al. Prevalence of high-risk human papillomavirus type 16 and 18 in oral and cervical cancers in population from Gujarat, West India. J Oral Pathol Med. 2014;43(4):293–7.CrossRef Patel KR, Vajaria BN, Begum R, Desai A, Patel JB, Shah FD, et al. Prevalence of high-risk human papillomavirus type 16 and 18 in oral and cervical cancers in population from Gujarat, West India. J Oral Pathol Med. 2014;43(4):293–7.CrossRef
Metadata
Title
Secular trends in incidence and mortality of cervical cancer in India and its states, 1990-2019: data from the Global Burden of Disease 2019 Study
Authors
Mayank Singh
Ravi Prakash Jha
Neha Shri
Krittika Bhattacharyya
Priyanka Patel
Deepak Dhamnetiya
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09232-w

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine